Minocycline for short-term neuroprotection

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 515-521

  Elewa, Hazem F ^a,c   Hilali, Rend ^a,c   Hess, David C ^a,b,c   Machado, Livia S ^a,c   Fagan, Susan C ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Minocycline; Neuroprotection; Stroke

Indexed keywords

LIVER ENZYME; MINOCYCLINE; NITROGEN; UREA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE MODEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG PENETRATION; DRUG SAFETY; ENZYME BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; LIVER DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PROTEINASE INHIBITION; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; UREMIA; URINARY EXCRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BRAIN INJURIES; CEREBROVASCULAR ACCIDENT; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; MATRIX METALLOPROTEINASES; MINOCYCLINE; NEUROPROTECTIVE AGENTS;

EID: 33645662983     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.515     Document Type: Article

References (55)

1. Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol 2001;14:349-53.
2. Martinez-Vila E, Sieria PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001;11(suppl 1):60-70.
3. Lees KR. Neuroprotection. Br Med Bull 2000;56:401-12.
4. DeGraba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurol Clin 2000;18(2):475-93.
5. Anonymous. Neuroprotection as initial therapy in acute stroke. Third report of an ad hoc consensus group meeting. The European ad hoc consensus group. Cerebrovasc Dis 1998;8(1):59-72.
6. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36.
7. Nelson ML, Chemical and biological dynamics of tetracyclines. Adv Dent Res 1998;12:5-11.
8. Coskey RJ. Acne: treatment with minocycline. Cutis 1976;17(4):799-801.
9. MD Consult Web page. Minocycline HCl. Available from www.mdconsult.com. Accessed June 20, 2005.
10. Chambers HF. Antimicrobial agents: protein synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Professional, 2001:1240-6.
11. Golub LM, McNamara TF, d'Angelo GD, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987;66:1310-14.
12. Gabler WL, Creamer HR. Suppression of human neutrophil functions by tetracyclines. J Periodontal Res 1991;26:52-8.
13. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blinded, placebo-controlled trial. Ann Intern Med 1995;122:81-9.
14. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemic with a wide therapeutic window. Proc Natl Acad Sci U S A 1999;96:13496-500.
15. Wang CX, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. Biomed Cent Neurol 2002;2:2-8.
16. Morimoto N, Shimazawa M, Yamashima T, Nagabi H, Hara H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res 2005;1044:8-15.
17. Xu L, Fagan SC, Waller JL, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats [online exclusive article]. BMC Neurol 2004;4:7. Available from www.biomedcentral.com/1471-2377/4/7.
18. Yrjänheikki J, Keinänen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998;95:15769-74.
19. Arvin KL, Han BH, Du Y, Lin S, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002;52:54-61.
20. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90.
21. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 2004;101:3071-6.
22. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-37.
23. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393-401.
24. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-42.
25. Wang CX, Yang T, Schuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res 2003;963:327-9.
26. Saivin S, Hovin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.
27. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implication for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-322.
28. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects of nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93:14014-19.
29. Lee SM, Yune TY, Kim SJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia coculture. J Neurochem 2004;91:568-78.
30. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Pro Natl Acad Sci U S A 2001;98:14669-74.
31. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125(pt 6):1297-308.
32. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-8.
33. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition of p38 MAPK in rat cerebellar granule neurons. Neurosci Lett 2001;315:61-4.
34. Furst DE. Update on clinical trials in the rheumatic diseases, Curr Opin Rheumatol 1998;10:123-8.
35. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two year double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-41.
36. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2004;55:756.
37. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
38. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Pro Natl Acad Sci USA 2003;100:10483-7.
39. Wang J, Wei Q, Wang C, Hill WD, Hess DC, Dong Z. Minocycline upregulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004;279:19948-54.
40. Matsukawa N, Yasuhara T, Xu L, et al. Minocycline protects neurons, but not astrocytes against oxygen glucose deprivation via apoptotic pathway [abstr]. Exp Neurol 2005;193:253.
41. Scarabelli TM, Stephanou A, Pasini E, et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of X1AP to smac/Diablo, and reduces the mitochondrial leakage of cytochrome C and smac/Diablo. J Am Coll Cardiol 2004;43(5):865-74.
42. Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 1993;64(8 suppl):819-27.
43. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease: SDD clinical research team. Ann N Y Acad Sci 1999;878:335-46.
44. Greenwald RA, Moak SA, Eamamurthy NS, Golub LM. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992;19(6):927-38.
45. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005;288:F91-7.
46. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 2003;23(8):879-94.
47. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 2000;98(3):73-81.
48. MacDonald H, Kelly RG, Allen S, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973;14:852-61.
49. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001;909:187-93.
50. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71.
51. Fagan SC, Edwards DJ, Borlongan C, et al. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-51.
52. Colovic M, Caccia S. Liquid Chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chrom B 2003;791:337-43.
53. Drew TJ, Altman R, Black K, Goldfield M. Minocycline for prophylaxis of infection with Neisseria meningitides: high rate of side effects in recipients. J Infect Dis 1976;133:194-8.
54. Gordon PH, Moore DH, Gelinas DF, et al. Placebo controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845-7.
55. Clark BJ, Hodgson CR, Dornbush AC, Hutchinson J. Minocycline administered intravenously: pharmacological activity and clinical experience. Curr Ther Res 1974;16:865-77.